Form 4: Lyell Immunopharma CEO Lynn Seely Acquires 175,000 Shares
SEC Form 4 Filing
Lyell Immunopharma's CEO, Lynn Seely, purchased 175,000 shares of common stock at a weighted average price of $0.6068 on March 14, 2025.
Summary
- On March 14, 2025, Lynn Seely, the President and CEO of Lyell Immunopharma, Inc., acquired 175,000 shares of the company's common stock.
- The shares were purchased at a weighted average price of $0.6068 per share.
- The price range for these shares was between $0.59980 and $0.62020.
- Following the transaction, Seely directly owns 712,500 shares of Lyell Immunopharma.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase is a positive signal, but it's a single transaction and doesn't provide a comprehensive view of the company's overall health.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. A purchase by the CEO is generally seen as a positive sign.
Stakeholder Impact
- The CEO's stock purchase may positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/14/2025 | Date of the transaction: Lynn Seely purchased 175,000 shares of Lyell Immunopharma common stock. |
| 03/18/2025 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.